The Microenvironmental and Metabolic Aspects of Sorafenib Resistance in Hepatocellular Carcinoma

EBioMedicine - Netherlands
doi 10.1016/j.ebiom.2019.102610
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Sorafenib in Hepatocellular Carcinoma

Clinical Medicine. Therapeutics
2009English

TARBP2-mediated Destabilization of Nanog Overcomes Sorafenib Resistance in Hepatocellular Carcinoma

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2019English

Cytotoxicity of Sorafenib in Human Hepatocellular Carcinoma Cells

Al-Azhar Journal of Pharmaceutical Sciences
2015English

Insulin Resistance and Other Metabolic Risk Factors in the Pathogenesis of Hepatocellular Carcinoma

Clinics in Liver Disease
Hepatology
2011English

TGFβ Signaling Confers Sorafenib Resistance via Induction of Multiple RTKs in Hepatocellular Carcinoma Cells

Molecular Carcinogenesis
Cancer ResearchMolecular Biology
2016English

MicroRNA‑223 Promotes Hepatocellular Carcinoma Cell Resistance to Sorafenib by Targeting FBW7

Oncology Reports
MedicineCancer ResearchOncology
2018English

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2008English

In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance Through Inhibition of Caspase-3–Mediated Apoptosis

Clinical Cancer Research
Cancer ResearchOncology
2017English

Phosphoprotein Enriched in Diabetes (PED/PEA15) Promotes Migration in Hepatocellular Carcinoma and Confers Resistance to Sorafenib

Cell Death and Disease
Molecular NeuroscienceImmunologyCell BiologyCancer ResearchCellularMedicine
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy